摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzo[b]thiophen-2-yl-(5-chloro-2-nitrophenyl)methanone | 848554-98-3

中文名称
——
中文别名
——
英文名称
benzo[b]thiophen-2-yl-(5-chloro-2-nitrophenyl)methanone
英文别名
1-Benzothiophen-2-yl-(5-chloro-2-nitrophenyl)methanone
benzo[b]thiophen-2-yl-(5-chloro-2-nitrophenyl)methanone化学式
CAS
848554-98-3
化学式
C15H8ClNO3S
mdl
——
分子量
317.752
InChiKey
WMIGHTFYJNGLBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    91.1
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Substituted piperazines of azepines, oxazepines and thiazepines
    申请人:He Xiaoqiang John
    公开号:US20060270656A1
    公开(公告)日:2006-11-30
    Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R 1 is hydrogen, (C 1-6 ) fluoroalkyl, (C 3-6 ) cycloalkyl, or (C 1-4 ) alkyl, wherein the (C 1-4 ) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH 2 CH 2 OH, —CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C 1-4 ) alkyl; R 2 is H, halogen, (C 1-6 ) fluoroalkyl, (C 3-6 ) cycloalkyl, OR 6 , SR 6 , NO 2 , CN, COR 6 , C(O)OR 6 , C(OH)R 6 , CONR 7 R 8 , phenyl or (C 1-6 ) alkyl, wherein the (C 1-6 ) alkyl is unsubstituted or substituted with a hydroxy; R 3 is hydrogen, (C 1-6 )fluoroalkyl , (C 3-6 ) cycloalkyl, (C 2-6 ) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C 1-4 )alkyl wherein (C 1-4 ) alkyl is unsubstituted or substituted with a phenyl; R 4 and R 5 are independently selected from hydrogen, halogen, (C 1-6 ) alkyl, (C 1-6 ) fluoroalkyl, OR 9 , SR 9 , NO 2 , CN, or COR 9 ; R 6 is hydrogen, (C 1-6 ) fluoroalkyl, or (C 1-6 ) alkyl; R 7 and R 8 are independently hydrogen, or (C 1-6 ) alkyl; R 9 is hydrogen, (C 1-6 ) fluoroalkyl, (C 1-6 ) alkyl; Alk is (C 1-4 ) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO 2 , or a bond; X is CH 2 , C═O, S, O, or SO 2 ; Z is hydrogen, halogen, (C 1-6 ) alkyl, (C 1-6 )fluoroalkyl, —OH, (C 1-6 ) alkoxy, (C 1-6 ) fluoroalkoxy, (C 1-6 ) alkylthio, (C 1-6 ) acyl, (C 1-4 )alkylsulfonyl, —OCF 3 , —NO 2 , —CN, carboxamido which may be substituted on the nitrogen by one or two (C 1-4 ) alkyl groups, and —NH 2 in which one of the hydrogens may be replaced by a (C 1-4 ) alkyl group and the other hydrogen may be replaced by either a (C 1-4 ) alkyl group, a (C 1-6 ) acyl group, or a (C 1-4 ) alkylsulfonyl group; the phenyl of R 1 , R 2 or R 3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R 3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R 3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D 2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).
    本文描述了式(I)的抗精神病化合物,其中: - 是一个可选的并五元或六元芳香环,其具有0-3个杂原子,独立地选自N,O和S; - R1是,(C1-6)氟烷基,(C3-6)环烷基或(C1-4)烷基,其中(C1-4)烷基未取代或取代了羟基,甲基,乙基,O OH,—CN,咪唑啉-2-基或四唑,其中四唑未取代或取代了(C1-4)烷基; - R2是H,卤素,(C1-6)氟烷基,(C3-6)环烷基,OR6,SR6,NO2,CN,COR6,C(O)OR6,C(OH)R6,CONR7R8,基或(C1-6)烷基,其中(C1-6)烷基未取代或取代了羟基; - R3是,(C1-6)氟烷基,(C3-6)环烷基,(C2-6)基,基,单环杂芳基,双环杂芳基或(C1-4)烷基,其中(C1-4)烷基未取代或取代了基; - R4和R5独立地选自,卤素,(C1-6)烷基,(C1-6)氟烷基,OR9,SR9, ,CN或COR9; - R6是,(C1-6)氟烷基或(C1-6)烷基; - R7和R8独立地是或(C1-6)烷基; - R9是,(C1-6)氟烷基或(C1-6)烷基; - Alk是(C1-4)烷基,未取代或取代了羟基; - Y是,SO2或键; - X是CH2,C═O,S,O或SO2; - Z是,卤素,(C1-6)烷基,(C1-6)氟烷基,—OH,(C1-6)烷基,(C1-6)氟烷基,(C1-6)烷基,(C1-6)酰基,(C1-4)烷基磺酰基,—OCF3,— ,—CN,羧酰胺,其上可能通过一个或两个(C1-4)烷基取代,以及—NH2,在其中一个可能被(C1-4)烷基取代,另一个可能被(C1-4)烷基,(C1-6)酰基或(C1-4)烷基磺酰基取代; - R1,R2或R3的基独立地未取代或取代了1-3个Z取代基; - R3的单环杂芳基未取代或取代了1-3个Z取代基; - R3的双环杂芳基未取代或取代了1-3个Z取代基; - 还描述了该化合物的盐,溶剂化合物和晶体形式。 还描述了将式(I)化合物用作多巴胺D2受体拮抗剂和治疗精神病和双相障碍的药物,以及式(I)化合物的制剂。
查看更多